Yüklüyor......
Strategies and Endpoints of Antifibrotic Drug Trials
There is an urgent need to develop antifibrotic therapies for chronic liver disease, and to clarify which endpoints in antifibrotic trials will be acceptable to regulatory agencies. AASLD sponsored an endpoints conference to help accelerate the efficient testing of antifibrotic agents and to develop...
Kaydedildi:
| Yayımlandı: | Hepatology |
|---|---|
| Asıl Yazarlar: | , , , |
| Materyal Türü: | Artigo |
| Dil: | Inglês |
| Baskı/Yayın Bilgisi: |
2015
|
| Konular: | |
| Online Erişim: | https://ncbi.nlm.nih.gov/pmc/articles/PMC4515973/ https://ncbi.nlm.nih.gov/pubmed/25626988 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1002/hep.27720 |
| Etiketler: |
Etiketle
Etiket eklenmemiş, İlk siz ekleyin!
|